Spyre Therapeutics, Inc.
SYRE
$14.60
$0.473.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -56.30M | -69.03M | -38.84M | -43.86M | -63.18M |
| Total Depreciation and Amortization | -- | -- | -- | -- | 0.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.30M | 29.26M | 5.75M | 11.84M | 34.01M |
| Change in Net Operating Assets | 10.80M | 10.35M | -29.16M | 3.47M | -1.86M |
| Cash from Operations | -37.20M | -29.42M | -62.25M | -28.54M | -31.04M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -170.54M | 42.74M | -120.52M | -104.96M | -35.27M |
| Cash from Investing | -170.54M | 42.74M | -120.52M | -104.96M | -35.27M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 225.93M | 13.08M | 495.00K | 4.39M | 84.84M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 0.00 | -- | -- | 169.21M | 84.56M |
| Repurchase of Preferred Stock | -- | -220.00K | -135.00K | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -329.00K | -78.00K | 0.00 | -1.43M | -5.79M |
| Cash from Financing | 225.60M | 12.78M | 360.00K | 172.17M | 163.61M |
| Foreign Exchange rate Adjustments | -15.00K | 16.00K | 0.00 | -4.00K | 18.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 17.84M | 26.12M | -182.41M | 38.66M | 97.32M |